News - Kowa Pharmaceuticals


Current filters:

Kowa Pharmaceuticals

Popular Filters

Kowa and Daiichi Sankyo to end joint marketing partnership in Japan


Privately-held Japanese drugmaker Kowa and pharma major Daiichi Sankyo (TYO: 4568) say they will be ending…

Asia-PacificCardio-vascularDaiichi SankyoKowa PharmaceuticalsLicensingLivaloMarkets & MarketingOlmetecPharmaceutical

Chugai licenses SGLT2 inhibitor CSG452 in Japan to Kowa and Sanofi


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG:…

Asia-PacificChugai PharmaceuticalCSG452DiabetesKowa PharmaceuticalsLicensingPharmaceuticalRocheSanofi

Lilly and Kowa's Livalo meets primary endpoint of LDL-C reduction


Presenting at the National Lipid Association's (NLA) Scientific Sessions in Scottsdale, Arizona, USA,…

Cardio-vascularEli LillyKowa PharmaceuticalsLivaloPharmaceuticalResearch

Teva buys out partner Kowa’s interest in Japanese JV for $150 million


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world’s largest generic drugmaker,…

Asia-PacificGenericsKowa PharmaceuticalsMergers & AcquisitionsTeva Pharmaceutical Industries

Back to top